Table 3 The information of HCC patients with PD-1 treatment.

From: FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers

Characteristics

PD-1 Treatment

P value

Effective (n = 45)

Ineffective (n = 24)

Age, mean ± sd

50.244 ± 11.458

52.583 ± 10.189

0.405

Gender, n (%)

  

0.989

Male

36 (52.2%)

20 (29%)

 

Female

9 (13%)

4 (5.8%)

 

Liver cirrhosis, n (%)

  

-

Yes

45 (65.2%)

24 (34.8%)

 

No

-

-

 

AFP, n (%)

  

0.561

Normal

12 (17.4%)

8 (11.6%)

 

Increased

33 (47.8%)

16 (23.2%)

 

ALT, n (%)

  

1.000

Normal

4 (5.8%)

2 (2.9%)

 

Increased

41 (59.4%)

22 (31.9%)

 

Tumor size, n (%)

  

0.816

≤ 5 cm

35 (50.7%)

20 (29%)

 

>5 cm

10 (14.5%)

4 (5.8%)

 

Tumor Number, n (%)

  

1.000

Single

44 (63.8%)

23 (33.3%)

 

Multiple

1 (1.4%)

1 (1.4%)

 

Tumor differentiation, n (%)

  

0.255

I + II

34 (49.3%)

15 (21.7%)

 

III + IV

11 (15.9%)

9 (13%)

 

T stage, n (%)

  

0.839

T1 + T2

27 (39.1%)

15 (21.7%)

 

T3 + T4

18 (26.1%)

9 (13%)

 

BCLC, n (%)

  

0.456

A

11 (15.9%)

4 (5.8%)

 

B

34 (49.3%)

20 (29%)

 
Back to article page